Methylecgonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Midostaurin. Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Fosamprenavir. The serum concentration of Cerivastatin can be increased when it is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Tranylcypromine. Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Crizotinib. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Triamterene. Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Zafirlukast. Indiplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium Citrate. Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Methylene blue may increase the hypotensive activities of Buprenorphine. The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Omeprazole. The serum concentration of Rifaximin can be increased when it is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyclothiazide. Perazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Lisdexamfetamine may increase the analgesic activities of Buprenorphine. The risk or severity of adverse effects can be increased when Methscopolamine is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Safrazine. The risk or severity of adverse effects can be increased when Methysergide is combined with Buprenorphine. Methamphetamine may increase the analgesic activities of Buprenorphine. The serum concentration of Buprenorphine can be increased when it is combined with Darunavir. Heroin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorothiazide. Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Ledipasvir can be increased when it is combined with Buprenorphine. Loxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Pentolinium is combined with Buprenorphine. Adipiplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Halazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Benperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Nortriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Procarbazine. Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Isavuconazonium. Ecgonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Buprenorphine may increase the serotonergic activities of Dapoxetine. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Thiamylal may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be increased when combined with Rifapentine. Remifentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Eliglustat. Hydroxyamphetamine may increase the analgesic activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Pivhydrazine. The serum concentration of Buprenorphine can be decreased when it is combined with Rilpivirine. The serum concentration of the active metabolites of Buprenorphine can be reduced when Buprenorphine is used in combination with Efavirenz resulting in a loss in efficacy. The metabolism of Buprenorphine can be decreased when combined with Topiroxostat. Opium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Mephedrone may increase the analgesic activities of Buprenorphine. Tiapride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Piritramide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Nintedanib can be increased when it is combined with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Amiodarone. Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Nicardipine. The metabolism of Buprenorphine can be decreased when combined with Sulfisoxazole. The risk or severity of adverse effects can be increased when Ergotamine is combined with Buprenorphine. Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Metoprolol can be increased when it is combined with Buprenorphine. Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Trans-2-Phenylcyclopropylamine. The serum concentration of Atazanavir can be decreased when it is combined with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Itraconazole. Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Ticagrelor. Droperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Loratadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Promazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Cholecalciferol. Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Amphetamine may increase the analgesic activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Telithromycin. Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Reserpine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Topiramate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Methohexital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Clotrimazole. The metabolism of Buprenorphine can be decreased when combined with Losartan. Etidocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Ketoconazole. Fospropofol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Pseudoephedrine may increase the analgesic activities of Buprenorphine. Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Sulfadiazine. The serum concentration of Buprenorphine can be decreased when it is combined with Bosentan. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium. The metabolism of Buprenorphine can be decreased when combined with Ticlopidine. Entacapone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Propantheline is combined with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Atomoxetine. Butethal may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Methadone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Osanetant may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydrochlorothiazide. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Mersalyl. The serum concentration of Buprenorphine can be increased when it is combined with Netupitant. Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Norflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Efonidipine. Buprenorphine may increase the serotonergic activities of Levomilnacipran. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Spironolactone. The risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Buprenorphine. Gabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Vecuronium is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Rolofylline. Trazodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Cinacalcet.